Panbela Therapeutics Inc. has entered into a sponsored research agreement with The University of Texas MD Anderson Cancer Center for the evaluation of polyamine metabolic inhibitor...

Iktos SA and Curreio Inc. have established a collaboration agreement using artificial intelligence (AI) for new drug design. Under this collaboration, Iktos will leverage its de novo generative design technology in combination with Curreio’s cryo-electron microscopy (EM) platform to facilitate the rapid design of novel preclinical drug candidates for an undisclosed target.

The University of Oxford and Selvita SA have established an integrated drug discovery collaboration in the area of Parkinson’s disease. Based on evidence implicating α-synuclein aggregates as the cause of Parkinson’s, the approach looks at the inability of cells to efficiently clear these aggregates, which may lead to the death of neurons and the emergence of characteristic symptoms of the disease. Promoting the ability of nerve cells to rid themselves of these aggregates therefore offers a possible therapeutic strategy for Parkinson’s disease.

Xtalpi Inc. has entered into an artificial intelligence (AI) drug discovery collaboration with Eli Lilly & Co. The collaboration, valued at up to $250 million in upfront and milestone payments, will leverage Xtalpi’s integrated AI capabilities and robotics platform to de novo design and deliver drug candidates for an undisclosed target. Xtalpi seeks to deliver a novel compound, which Lilly will pursue in clinical and commercial development.

Hilleman Laboratories Singapore Pte Ltd. and the Agency for Science, Technology and Research (A*STAR) have established a collaboration to explore using novel circular ribonucleic acid (circRNA) technology to develop a Nipah virus vaccine and to validate the technology platform for application for other infectious diseases pathogens.

Hanall Biopharma Co. Ltd. and Daewoong Pharmaceutical Co. Ltd. have entered into...

Angelini Pharma SpA and JCR Pharmaceuticals Co. Ltd. have entered into an exclusive global development and commercialization agreement for the development of novel biologic therapies that applies J-Brain Cargo blood-brain barrier penetrating technology for the treatment of epilepsy, applying undisclosed effectors.